Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Fri Jun 25 21:41:46 UTC 2021
by
admin
on
Fri Jun 25 21:41:46 UTC 2021
|
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
SEV29N8JND
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SEV29N8JND
Created by
admin on Fri Jun 25 21:41:46 UTC 2021 , Edited by admin on Fri Jun 25 21:41:46 UTC 2021
|
PRIMARY |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_598 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET |
IC50
|
||
|
INHIBITOR->OFF-TARGET | |||
|
NON-INHIBITOR->OFF TARGET | |||
|
INHIBITOR->OFF-TARGET |
|
||
|
INHIBITOR->OFF-TARGET |
IC50
|
||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET |
Avanafil inhibited hERG current in a concentration-dependent manner with IC50 of 15.8 ?M, which corresponded to exposures approximately 290-fold above the unbound Cmax (~26 ng/mL, 0.054 ?M) in human subjects after the maximum recommended single oral dose at 200 mg.
IC50
|
||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
NON-INHIBITOR->OFF TARGET |
did not predict QTc prolongation, by inhibition of the hERG channel at clinically relevant concentrations
|
||
|
NON-INHIBITOR->OFF TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR->OFF-TARGET | |||
|
NON-INHIBITOR->OFF TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET |
IC50
|
||
|
NON-INHIBITOR->OFF TARGET | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
TRANSPORTER -> NON-INHIBITOR | |||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR->OFF-TARGET |
|
||
|
NON-INHIBITOR->OFF TARGET |
IC50
|
||
|
INHIBITOR->OFF-TARGET |
IC50
|
||
|
NON-INHIBITOR->OFF TARGET |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR->OFF-TARGET |
MAY BE RESPONSIBLE FOR QT PROLONGATION
IC50
|
||
|
NON-INHIBITOR->OFF TARGET |
9% inhibition at 3 MICROMOLAR
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
NON-INHIBITOR->OFF TARGET |
IC50
|
||
|
NON-INHIBITOR->OFF TARGET | |||
|
INHIBITOR->OFF-TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
||
|
NON-INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TARGET |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|